Clinical trials are an essential tool in modern medicine. Clinical trials are research investigations in which people voluntarily participate in studies for new treatments and interventions to prevent, diagnose or manage blood disorders. They are crucial for the development of new medical treatments and help determine if new medicines are effective, safe and/or better than the current treatments available.
Clinical trials aim to answer the following questions in a controlled environment :
Clinical trials are the final step in a long process that begins with research in a laboratory.
Clinical trials aim to answer the following questions in a controlled environment :
- Does the treatment work?
- Is the treatment safe - does it have significant side effects?
- Is the treatment ‘better’ that other treatments already available?
- If better, does it have less side effects?
- Does it work faster?
- Is it more cost-effective than other treatments?
Clinical trials are the final step in a long process that begins with research in a laboratory.
Current Clinical Trials
The Perth Blood Institute’s Clinical Trials Unit is a very active research unit, running numerous clinical trials and performing state-of-the-art research into bleeding and clotting disorders and blood cancers. We are also actively working on initiating new studies - so check back often!
We are regularly contacted to take part in new clinical trials for improved treatments for blood disorders, and we are keen to do so, as this provides Western Australians with the opportunity to access new treatments.
If you or a member of your family suffers from a blood disorder listed below you and would like to be considered for enrolment for participation in a clinical trial, please contact us on (08) 9200 4904, email info@pbi.org.au or click below button to register online.
We are regularly contacted to take part in new clinical trials for improved treatments for blood disorders, and we are keen to do so, as this provides Western Australians with the opportunity to access new treatments.
If you or a member of your family suffers from a blood disorder listed below you and would like to be considered for enrolment for participation in a clinical trial, please contact us on (08) 9200 4904, email info@pbi.org.au or click below button to register online.
Blood Cancers and Related Disorders
Chronic Lymphocytic Leukaemia (CLL)
Multiple Myeloma
Non-Hodgkin Lymphoma (NHL)
Chronic Myeloid Leukaemia (CML)
Myelofibrosis (MF)
Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS)
- ACERTA ACE-CL-309 Study: A Randomized, Multi-Centre, Open-Label Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed of Refractory Chronic Lymphocytic Leukemia. For further information, please click here or contact us on (08) 9200 4904. ACTIVE AND RECRUITING!
- ABBVIE M15-889 Study: A Study Evaluating Venetoclax in Subjects with Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Had No Repsonse to Previous Cancer Treatments. For further information, please click here or contact us on (08) 9200 4904.
ACTIVE AND RECRUITING! - MURANO GO28667 Study: A Study of GDC-0199 (ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. For further information, please click here or contact us on (08) 9200 4904.
ACTIVE, BUT NOT RECRUITING.
Multiple Myeloma
- New Smouldering Myeloma Study: A Phase 3 study evaluating a CD38 antibody for Smouldering Multiple Myeloma. COMING SOON!
- New Myeloma Study: A Phase 3 combination study evaluating a CD38 antibody for relapsed or refractory Multiple Myeloma. COMING SOON!
- New Myeloma Study: A Phase 3 combination study evaluating a CD38 antibody for newly-diagnosed Multiple Myeloma. COMING SOON!
- INTREPID-1 Study: A Phase 1b Study Evaluating Oprozomib in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. For further information, please click here or contact us on (08) 9200 4904. ACTIVE AND RECRUITING!
- ABBVIE M14-031 BELLINI Study: A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who are Recieving Bortezomib and Dexamethasone. For further information, please click here or contact us on (08) 9200 4904. ACTIVE, BUT NOT RECRUITING.
- MAIA MMY3008 Study: A Phase 3 Study comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. For further information, please click here or contact us on (08) 9200 4904. ACTIVE, BUT NOT RECRUITING.
Non-Hodgkin Lymphoma (NHL)
- B-MIND Study: A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine Versus Rituximab with Bendamustine in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL). For further information, please click here or contact us on (08) 9200 4904. COMING SOON!
- CHRONOS-3 Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Copanlisib in Combination with Rituximab in Patients with Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL). For further information, please click here or contact us on (08) 9200 4904. ACTIVE AND RECRUITING!
- ACERTA ACE-LY-308 Study: A Study of Bendamustine and Rituximab Alone Versus in Combination with Acalabrutinib in Subjects with Previously Untreated Mantle Cell Lymphoma. For further information, please click here or contact us on (08) 9200 4904. ACTIVE AND RECRUITING!
- To see previous NHL studies performed by PBI, click here.
Chronic Myeloid Leukaemia (CML)
- ENESTswift CAMN107AAU04 Study: A multicenter, single arm study to assess efficacy and safety of nilotinib 300mg BD in patients with Philadelphia positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) who are intolerant to prior tyrosine kinase inhibitors (TKIs). For further information, please click here or contact us on (08) 9200 4904. CLOSED
Myelofibrosis (MF)
- ReTHINK CINC424A2353 Study: A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients with High Molecular Risk Mutations. For further information, please click here or contact us on (08) 9200 4904. CLOSED
- PERSIST2 PAC326 Study: Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia. For further information, please click here or contact us on (08) 9200 4904. CLOSED.
Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS)
- New FLT3+ Acute Myeloid Leukemia Study: COMING SOON!
- MDS BLAST TL32711-RAN-0094-PTL Study: Study of Azacitidine with or without Birinapant in subjects with MDS or CMMoL. For further information, please click here or contact us on (08) 9200 4904. CLOSED.
Bleeding, Clotting and Related Blood Disorders
Venous Thromboembolism (VTE)
Immune Thrombocytopenic Purpura (ITP)
Microangiopathic Thrombocytopenia (MAT), including TTP and aHUS
Haemophilia A
Paroxsymal Noctural Hemoglobinuria (PNH)
Anaemia and Iron Overload
- COSIMO Study: A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients with Active Cancer. For further information, please click here or contact us on (08) 9200 4904. COMING SOON!
- MARINER RIVAROXDVT3002 Study: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER). For further information, please click here or contact us on (08) 9200 4904. CLOSED
- Anticoagulant Reversal and Events (ARES) Collaborative: A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants. For further information, please click here, visit www.aptin.org or contact us on (08) 9200 4904. ACTIVE AND RECRUITING!
- APEX 11-019 Study: Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study). For further information, please click here or contact us on (08) 9200 4904. CLOSED
Immune Thrombocytopenic Purpura (ITP)
- SPRITE: TRA117260 Study: A Multicentre, Single-arm, Open Label Study Evaluating the Efficacy and Safety of Eltrombopag (RevoladeTM) in Patients with Early Refractory Immune Thrombocytopenia Within 6 Months of Diagnosis. For further information, please contact us on (08) 9200 4904. ACTIVE, BUT NOT RECRUITING.
- Rigel C-935788-049 Study: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura. For further information, please click here or contact us on (08) 9200 4904. ACTIVE, BUT NOT RECRUITING.
- Rigel C-935788-047 Study: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura. For further information, please click here or contact us on (08) 9200 4904. CLOSED
Microangiopathic Thrombocytopenia (MAT), including TTP and aHUS
- APMAT1 Study: A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network. For further information, please click here, visit www.aptin.org or contact us on (08) 9200 4904.
ACTIVE AND RECRUITING!
Haemophilia A
- CSL627_3001 Study: A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rFVIII-SingleChain, CSL627) in Subjects with Severe Hemophilia A. For further information, please click here or contact us on (08) 9200 4904. To see previous haemophila studies performed by PBI, click here. ACTIVE, BUT NOT RECRUITING.
- BAX855 PROPEL Study: A Phase 3 Prospective, Randomized, Multi-Centre Clinical Study Comparing the Saftey and Efficacy of BAX855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects with Severe Hemophilia A. For further information, please click here or contact us on (08) 9200 4904. To see previous haemophila studies performed by PBI, click here. ACTIVE, BUT NOT RECRUITING.
- HAVEN-3 Study: A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Verus No Prophylaxis in Hemophilia Participants Without Inhibitors. For further information, please click here or contact us on (08) 9200 4904. To see previous haemophila studies performed by PBI, click here. ACTIVE, BUT NOT RECRUITING.
Paroxsymal Noctural Hemoglobinuria (PNH)
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry: For further information, please click here or contact us on (08) 9200 4904.
ACTIVE, BUT NOT RECRUITING. - ALXN1210-PNH-301 Study: ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naive Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). For further information, please click here or contact us on (08) 9200 4904. ACTIVE, BUT NOT RECRUITING.
Anaemia and Iron Overload
- No Trials Currently Recruiting. To see previous anaemia and iron overload studies performed by PBI, click here.
|
|